The researchers pooled data from six genome-wide association studies, covering 4,710 people with AML and 12,938 controls. That matters because AML is not a common cancer, and studying inherited risk in a rare disease is a bit like trying to learn traffic patterns from three cars and a bicycle. Bigger numbers help.
They found one new risk locus for AML overall at 2p23.3, in a neighborhood that includes DNMT3A [1]. If that gene rings a bell, it should. DNMT3A is one of the best-known players in clonal hematopoiesis and AML biology. In plain English, clonal hematopoiesis means a blood stem cell picks up a mutation, gets a growth edge, and starts producing an outsized family of descendants. It is less "everything is fine" and more "one cousin has quietly taken over the reunion" [3-5].
This study also found three subtype-specific risk loci:
- 1q23.3 for AML with chromosome 5 and/or 7 deletions
- 2q33.3 for cytogenetically complex AML
- 2p21 for another complex-karyotype subgroup [1]
That subtype piece is the real eyebrow-raiser. AML is not one disease wearing different hats. It is more like a messy extended family of diseases, and this paper says some inherited risk factors may choose sides early.
AML is not one villain
If you only remember one thing, make it this: the paper helps separate inherited risk variants from the mutations that leukemia cells acquire later.
Those are not the same thing. A common variant does not mean "you have leukemia hiding in the basement." It means your blood-making system may be a little more permissive to certain bad outcomes if the wrong additional hits come along. Think of it as slightly worse weather for a fire-prone forest. A dry week is not the fire. It just makes the spark matter more.
One especially interesting twist is that the 2p23.3 signal was also linked to survival, not just risk [1]. That does not prove cause and effect by itself, but it hints that the inherited backdrop may shape not only who gets AML, but how the disease behaves after it arrives. Cancer biology, naturally, refuses to do one job when it can do three.
The prequel matters
This paper also connects AML risk to clonal hematopoiesis, which has become one of the most useful ideas in blood cancer research over the last few years. Several studies have shown that age-related blood clones are common and biologically meaningful, and that some of those clones sit on a path toward myeloid cancers [3-5].
That is why the DNMT3A connection feels important. It suggests AML does not always appear out of nowhere like a burglar in a movie. Sometimes there is a long, sneaky prequel. The blood system may spend years accumulating small advantages, small imbalances, and small clonal expansions before the full leukemia story starts.
Recent reviews have made the same point from different angles: AML GWAS has been underpowered for years because AML is rare and heterogeneous, and clonal hematopoiesis offers a bridge between inherited predisposition and later malignant transformation [2,5]. This new paper gives that bridge a few more steel beams.
Why this could matter in the real world
No, this does not mean we are about to hand everyone an "AML horoscope" based on a cheek swab. Biology is rude, and risk prediction is harder than social media ads make it look. But if these findings hold up and expand across populations, they could matter in practical ways.
They could help refine risk models, especially when combined with age, family history, blood counts, and markers of clonal hematopoiesis. They could improve how researchers define AML subgroups for prevention studies. And they may help explain why some people drift toward specific forms of AML while others, carrying different inherited backgrounds, do not.
There is also a more human payoff. Families dealing with leukemia often want a straight answer to a crooked question: "Why this person?" Most of the time, science has to shrug and mutter something unsatisfying. Studies like this do not solve that mystery completely, but they replace a little shrugging with actual mechanism. In cancer research, that counts as progress and a minor miracle.
References
-
Ranasinghe D, Lin WY, Fordham SE, et al. Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia. Blood. 2026. DOI: 10.1182/blood.2025031266. PubMed: 41610418
-
Marrero RJ, Lamba JK. Current Landscape of Genome-Wide Association Studies in Acute Myeloid Leukemia: A Review. Cancers (Basel). 2023;15(14):3583. DOI: 10.3390/cancers15143583. PMCID: PMC10377605
-
Niroula A, Sekar A, Murakami MA, et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021;27(11):1921-1927. DOI: 10.1038/s41591-021-01521-4
-
Stacey SN, Zink F, Halldorsson GH, et al. Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis. Nat Genet. 2023;55(12):2149-2159. DOI: 10.1038/s41588-023-01555-z. PMCID: PMC10703693
-
Beeler JS, Walter MJ, Bolton KL. Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies. Haematologica. 2026. DOI: 10.3324/haematol.2025.287488. PubMed: 41641638
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.